Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
FOR IMMEDIATE RELEASE
Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
SAN DIEGO, CA – January 7, 2014 – Arcturus Therapeutics, Inc., an industry leader in RNA technologies for the treatment of rare orphan diseases, today announced that Joseph E. Payne, President & CEO will be presenting at the Biotech Showcase in San Francisco on Monday, January 13, 2014 at 11:30 a.m. PST, at the Parc 55 Wyndham Union Square Hotel in Track A – Hearst (3rd Floor). The presentation will provide a corporate overview and summarize the key accomplishments of 2013, including:
- Development of a novel, potent and safe RNA Therapeutics platform called LUNARTM technology – a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, and microRNA oligotherapeutics
- Ownership of Unlocked Nucleic Acid (UNA) chemistry technology and patent portfolio (32 patents, USPTO granted) enabling the targeting of any gene in the human genome
- Key milestones achieved: Superior in vivo potency data, excellent safety profile as demonstrated in a multiple-dose rat toxicology study, high encapsulation efficiency of RNA cargo greater than 95%, and GMP-readiness of the drug product manufacturing process.
About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Calif., Arcturus Therapeutics is focused on RNA technologies for the treatment of rare diseases and high unmet medical needs. Arcturus has developed of a novel, potent and safe RNA Therapeutics platform called LUNAR TM , a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, and microRNA oligotherapeutics. The company owns Unlocked Nucleic Acid (UNA) chemistry technology and patent portfolio (32 patents, USPTO granted) enabling the targeting of any gene in the human genome For more information, visit us at www.ArcturusRx.com.
About Biotech ShowcaseTM 2014
Biotech Showcase is an annual investing and partnering benchmark for life science executives and investors devoted to providing private and public biotechnology and life sciences companies, investors and pharmaceutical executives with an opportunity to present and meet in one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world. Now in its Sixth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule face to face partnering meetings and networking. The attendees to the showcase include private and public equity investors, bankers, analysts, biopharmaceutical industry executives and other industry professionals. The event is being held at the Parc 55 Wyndham San Francisco – Union Square.
# # #